During the Psoriasis Hub Steering Committee meeting in May 2024, Alice Gottlieb chaired a session on patient and physician expectations – from diagnosis to the treatment of psoriatic disease. The discussion featured patients Jody Quinn and Hellen Wangui.

In the first part of the discussion, diagnosis was discussed. Quinn and Wangui also shared about their journey to diagnosis and associated barriers in diagnosis. Gottlieb discussed why diagnosis can be delayed and how this could be improved.

In the second part of the discussion, treatment of psoriatic disease was discussed, including difficulties in access to treatment, personal experiences with treatment, and side effects of treatment. Quinn and Wangui also shared how physicians could have made their treatment journey easier.

Hosted on Acast. See acast.com/privacy for more information.

During the Psoriasis Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.

The recorded discussion was chaired by Paolo Gisondi, and featured Alice Gottlieb and Yukari Okubo. The steering committee discussed recent approvals of systemic agents for psoriatic disease, including efficacy and safety data of bimekizumab and deucravacitinib. They also spoke about how to avoid and treat oral candidiasis infections in patients treated with interleukin 17 inhibitors.

Hosted on Acast. See acast.com/privacy for more information.

During the 25th World Congress of Dermatology 2023, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Mark Lebwohl, Mount Sinai, New York, U.S. We asked about the long-term efficacy of deucravacitinib.

Lebwohl discusses the data at 112 weeks of continuous deucravacitinib treatment. He also mentions how, by blocking tyrosine kinase 2, deucravacitinib differs from standard therapies, maintaining a high level of efficacy over time.

Hosted on Acast. See acast.com/privacy for more information.

During the 31st European Academy of Dermatology and Venereology (EADV) Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Paolo Gisondi, University Hospital of Verona, Verona, IT, and Jose-Manuel Carrascosa, Germans Trias i Pujol University Hospital, Barcelona, ES. We asked, Is a treatment goal of PASI100 appropriate in psoriasis management?

Carrascosa opens by discussing PASI100 as an optimal treatment goal but notes that this may not be achievable in all patients and may be a possible cause of disappointment when there is failure to meet it. Gisondi agrees and goes on to highlight the importance of distinguishing between an optimal treatment target and a realistic treatment target. He suggests that more achievable goals, such as PASI90, may be more appropriate. Gisondi and Carrascosa finish by discussing the importance of considering other outcomes, such as quality of life and disease modification, when assessing treatment goals.

Hosted on Acast. See acast.com/privacy for more information.